OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Ahmed on the Rationale for Investigating Real-World Outcomes of Brexu-Cel in R/R MCL

July 19th 2023

Nausheen Ahmed, MD, discusses the rationale for investigating real-world outcomes of patients with relapsed/refractory mantle cell lymphoma treated with brexucabtagene autoleucel.

Dr Desai on the Evolution of Divarasib in KRAS G12C-mutated CRC

July 19th 2023

Jayesh Desai, MBBS, FRACP, discusses the evolution of divarasib, highlighting the rationale for combining the KRAS G12C inhibitor with cetuximab in patients with advanced colorectal cancer harboring KRAS G12C mutations in a phase 1b study.

Dr Damodaran on the ELAINE-3 Trial in Patients With ESR1-Mutated ER+/HER2– Metastatic Breast Cancer

July 19th 2023

Senthil Damodaran, MD, PhD, discusses the rationale for the phase 3 ELAINE-3 trial in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

Dr Cairo on the Safety Profiles of T-DM1 vs T-DXd in HER2+ Metastatic Breast Cancer

July 19th 2023

Michelina Cairo, MD, discusses the adverse effect profiles of trastuzumab emtansine and trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.

Dr Signoretti on the Development of Novel Biomarkers in RCC Using Tissue-Based Analyses

July 19th 2023

Sabina Signoretti, MD, discusses research into the development of novel spatial biomarkers in renal cell carcinoma utilizing tissue-based in situ analyses.

Dr Hannan on the Advantages of Stereotactic Radiation in Primary and Locally Advanced RCC

July 19th 2023

Raquibul Hannan, MD, PhD, discusses the advantages of stereotactic radiation in primary or locally advanced renal cell carcinoma.

Dr Ged on the Background of the ORCHID Trial in BAP1-Mutated Metastatic RCC

July 18th 2023

Yasser Mohamed Ali Ged, MBBS, discusses the background of launching the phase 2 ORCHID trial evaluating olaparib monotherapy in patients with metastatic renal cell carcinoma harboring BAP1 or other DNA repair gene mutations.

Dr Taieb on the Safety Proline of TAS-102/Bevacizumab in Refractory mCRC

July 18th 2023

Julien Taieb, MD, PhD, discusses the safety profile associated with trifluridine/tipiracil with bevacizumab in refractory metastatic colorectal cancer.

Dr Lowentritt on the Rationale for Investigating Real-World PSA Response to AR Inhibitors in mCSPC

July 18th 2023

Benjamin H. Lowentritt, MD, FACS, discusses the background and rationale for conducting a real-world retrospective study of prostate-specific antigen responses generated from second-generation androgen receptor inhibitors in patients with metastatic castration-sensitive prostate cancer.

Dr Zhang on the Potential Use of RNA Sequencing to Improve Treatment Selection in Advanced RCC

July 18th 2023

Tian Zhang, MD, MHS, discusses whether the use of RNA sequencing to identify biologic cluster assignment could improve first-line treatment selection in metastatic renal cell carcinoma.

Dr Sun on the Relationship Between Clonal Hematopoiesis and Cardiovascular Disease in RCC

July 18th 2023

Maxine Sun, PhD, MPH, discusses the association between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma

Dr Matous on Ongoing Multiple Myeloma Clinical Trials at Colorado Blood Cancer Institute

July 17th 2023

Jeffrey V. Matous, MD, discusses upcoming and ongoing clinical trials in multiple myeloma being conducted at the Colorado Blood Cancer Institute.

Dr Danilov on Questions Remaining Across the Treatment Landscape of MCL

July 17th 2023

Alexey Danilov, MD, PhD, discusses lingering questions that remain across the treatment landscape of mantle cell lymphoma.

Dr Danish on the Challenges of Radiation Treatment in Lung and Bone Cancers

July 17th 2023

Adnan F. Danish, MD, discusses unmet needs in the treatment of patients with lung and bone cancers, and how unmet needs within this patient population are being addressed with the utilization of SCINTIX radiation technology.

Dr Tarantino on the Expansion of Treatment Options Post-CDK4/6 Inhibition in HR+ Breast Cancer

July 17th 2023

Paolo Tarantino, MD, discusses the expansion and selection of effective treatment options for patients with hormone receptor-positive breast cancer who progressed on a CDK 4/6 inhibitor.

Dr Raez on the Effect of the NADIM II Trial on the Neoadjuvant Treatment Paradigm in NSCLC

July 17th 2023

Luis E. Raez, MD, discusses how findings from the phase 2 NADIM II trial inform the neoadjuvant treatment paradigm in non–small cell lung cancer.

Dr Komrokji on the Implications of the COMMANDS Trial in MDS

July 14th 2023

Rami Komrokji, MD, discusses the clinical implications of the phase 3 COMMANDS trial in patients with very low–, low-, or intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.

Dr Basin on the Methods for Investigating Hsp70 Inhibition in Belzutifan-resistant in RCC

July 14th 2023

Michael Basin, MD, discusses the design of a preclinical investigation into the pharmacological inhibition of the molecular chaperone Hsp70 and how it relates to belzutifan resistance in clear cell renal cell carcinoma.

Dr Matous on the Benefit Derived from the IKEMA Trial in R/R Multiple Myeloma

July 14th 2023

Jeffrey V. Matous, MD, discusses the benefit derived from the phase 3 IKEMA trial in patients with relapsed/refractory multiple myeloma, highlighting the key factors to take into account when evaluating patients for relapsed/refractory disease within this treatment space.

Dr Danilov on Therapeutic Options After BTK Inhibitors in MCL

July 14th 2023

Alexey Danilov, MD, PhD, discusses treatment developments for patients with mantle cell lymphoma who have progressed on BTK inhibitors.